To demonstrate the interaction among TM4SF1, PKCα, and DNM2, we examined the levels of PKCα, p-PKCα, DNM2, and TM4SF1 proteins in platelets from breast cancer patients treated with a PKCα inhibitor or an anti-TM4SF1 neutralizing antibody. This evidence concerns the gene DNM2 and breast carcinoma.